日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer

针对 COVID-19 疾病的气雾剂干预措施的开发:通过雾化器施用的可溶性 ACE2 (APN01) 的耐受性

Robert H Shoemaker, Reynold A Panettieri Jr, Steven K Libutti, Howard S Hochster, Norman R Watts, Paul T Wingfield, Philipp Starkl, Lisabeth Pimenov, Riem Gawish, Anastasiya Hladik, Sylvia Knapp, Daniel Boring, Jonathan M White, Quentin Lawrence, Jeremy Boone, Jason D Marshall, Rebecca L Matthews, B

Development of a novel, pan-variant aerosol intervention for COVID-19

开发一种新型、泛变体气溶胶干预措施来治疗 COVID-19

Robert H Shoemaker, Reynold A Panettieri Jr, Steven K Libutti, Howard S Hochster, Norman R Watts, Paul T Wingfield, Philipp Starkl, Lisabeth Pimenov, Riem Gawish, Anastasiya Hladik, Sylvia Knapp, Daniel Boring, Jonathan M White, Quentin Lawrence, Jeremy Boone, Jason D Marshall, Rebecca L Matthews, B

Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model

NSAID、NO-NSAID 及 NSAID 加二氟甲基鸟氨酸对化学诱发膀胱癌模型的预防作用

Holly L Nicastro, Clinton J Grubbs, M Margaret Juliana, Ann M Bode, Mi-Sung Kim, Yan Lu, Ming You, Ginger L Milne, Daniel Boring, Vernon E Steele, Ronald A Lubet

Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668

Akt 抑制剂 SR13668 的 0 期临床化学预防试验

Joel M Reid, Chad A Walden, Rui Qin, Katie L Allen Ziegler, John L Haslam, Roger A Rajewski, Roger Warndahl, Cindy L Fitting, Daniel Boring, Eva Szabo, James Crowell, Marjorie Perloff, Ling Jong, Brent A Bauer, Sumithra J Mandrekar, Matthew M Ames, Paul J Limburg; Cancer Prevention Network